Market Cap (In USD)
52.08 Million
Revenue (In USD)
2.08 Million
Net Income (In USD)
-5.48 Million
Avg. Volume
636.00
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.189-3.44
- PE
- -
- EPS
- -
- Beta Value
- 0.416
- ISIN
- US67092M1255
- CUSIP
- 67092M125
- CIK
- 1676047
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Gareth Sheridan
- Employee Count
- -
- Website
- http://nutriband.com
- Ipo Date
- 2021-10-01
- Details
- Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. The company has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. Nutriband Inc. was incorporated in 2016 and is headquartered in Orlando, Florida.
More Stocks
-
HOFBFHofseth BioCare ASA
HOFBF
-
ELRXFAB Electrolux (publ)
ELRXF
-
ECRFFCartier Resources Inc.
ECRFF
-
MEDHLP
-
CACO
-
016610
-
BIOCONBiocon Limited
BIOCON
-
0JSPLTC Properties, Inc.
0JSP